Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Healthcare
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Cardiol Therapeutics Inc > Anything new!?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(79)
•••
Comment by Youhillmanon Apr 12, 2021 11:46am
150 Views
Post# 32977468

RE:RE:RE:Anything new!?

RE:RE:RE:Anything new!?

oh it's very real MapleLaugh, I've owned it for 2+ years now and kept averaging down to the low $3.00+ range......everyone should be paying attention to the very comprehensive report put out by Leede Jones Gable....they have a 12 month target of $12.50.....I trust their expert opinion and so do the others on this board...far more then the garbage you and GiveMEmoney post!

MapleLaugh...the joke is on you....


Mapleleaf57 wrote: yup your right, Youhillman.. 6 figures my *ss look at the great news today about the Phase 1 results,, Fantastic news and its poping .. you know Givememoney is right come back in a few months,,,, 6 figures you wish,,,  

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities